Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes

This study has been completed.
Alcon Research
Information provided by (Responsible Party):
Daniel S. Durrie, MD, Durrie Vision Identifier:
First received: October 27, 2008
Last updated: September 19, 2012
Last verified: September 2012
The primary objective of this study is to compare two post operative drop regimens for the management of dry eye and control of healing using FDA-approved ophthalmic solutions.

Condition Intervention Phase
Dry Eye
Other: Systane Ultra
Other: Bausch and Lomb Sensitive Eyes
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes

Resource links provided by NLM:

Further study details as provided by Durrie Vision:

Primary Outcome Measures:
  • Tear osmolarity [ Time Frame: 2 week, 1 month ]

Secondary Outcome Measures:
  • Tear Break Up Time [ Time Frame: 2 week, 1 month post op ]

Enrollment: 30
Study Start Date: October 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Systane Ultra
Other: Systane Ultra
Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
Other Name: Natural Tears
Active Comparator: 2
Bausch and Lomb Sensitive Eyes
Other: Bausch and Lomb Sensitive Eyes
Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
Other Name: Saline Solution

Detailed Description:
This comparison will be made between bilateral eyes of the same patient following excimer laser ablation using the FDA-approved LADARVision 4000 Excimer Laser System or the WaveLight ALLEGRETTO WAVE™ Excimer Laser System. Post operative questionnaires regarding the use of the drops will be compared. Tear osmolarity and tear breakup time will be evaluated using Tear Lab and OQAS II.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects must be a suitable candidate for FDA Approved LASIK.
  • Subjects must have a stable refraction as documented by previous clinical records.
  • Subjects who wear soft contact lenses must discontinue wear at least 3 days prior to preoperative exam or surgery.
  • Subjects who wear gas permeable contact lenses must discontinue wear at least 3 weeks prior to preoperative exam or surgery.
  • Subjects must be at least 18 years of age.
  • Subjects must be willing and able to return for scheduled follow up examinations each day after surgery at the specified time.
  • Subjects must sign and be given a copy of the written Informed Consent form.

Exclusion Criteria:

  • Subjects for whom either eyes do not meet all inclusion criteria and either eye meets any exclusion criteria.
  • Subjects with clinically significant dry eye syndrome or clinically significant blepharitis in either eye.
  • Subjects with clinically significant anterior segment pathology, including clinically significant cataracts, corneal scarring or neovascularization in either eye.
  • Subjects who have undergone previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye.
  • Subjects who have a history of Herpes zoster or Herpes simplex keratitis.
  • Subjects on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing, any immunocompromised subjects, and subjects with clinically significant atopic disease, connective tissue disease, or uncontrolled diabetes.
  • Subjects with a history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP>25 mm Hg in either eye.
  • Subjects with macular pathology in either eye.
  • Subjects who are pregnant, lactating, or planning to be pregnant during the course of the study.
  • Subjects with known sensitivity to planned study concomitant medications.
  • Subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.
  • Use of ocular drugs, other than study medications, during the study and within 30 days prior to study entry or any other ocular medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00781092

Sponsors and Collaborators
Durrie Vision
Alcon Research
Principal Investigator: Daniel S. Durrie, MD Durrie Vision
  More Information

Additional Information:
Responsible Party: Daniel S. Durrie, MD, President, Durrie Vision Identifier: NCT00781092     History of Changes
Other Study ID Numbers: SUSE-01
Study First Received: October 27, 2008
Last Updated: September 19, 2012

Keywords provided by Durrie Vision:
Dry Eyes
Laser Vision Correction

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions
Ophthalmic Solutions processed this record on May 22, 2017